Actinium Ac 225 Vipivotide Tetraxetan

Phase 2Small molecule

Actinium Ac 225 Vipivotide Tetraxetan is one of 55 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Prostate Adenocarcinoma

#DrugCompanyPhaseTrials

Zytiga

Johnson & Johnson

Phase 3

1 2

Estrace

Novo Nordisk

Phase 3

1 3

Depo-Provera

Eli Lilly

Phase 3

1 4

Zoladex

TTerSera Therapeutics LLC

Phase 3

4 5

Tecentriq

Eulexin

4 7

Keytruda

Sutent

Lupron

EEastern Cooperative Oncology Group

Phase 3

2 10

Effexor

WWyeth-Lederle Vaccines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 2Recruiting

Prostate Adenocarcinoma

NCT07150715

Clinical

Trials by Indication[1]

Prostate Adenocarcinoma1 trial

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07150715·107 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Actinium Ac 225 Vipivotide Tetraxetan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Actinium Ac 225 Vipivotide Tetraxetan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Actinium Ac 225 Vipivotide Tetraxetan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJonsson Comprehensive Cancer Center

Actinium Ac 225 Vipivotide Tetraxetan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Prostate Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News